Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Mineralys Therapeutics (MLYS) presented data at the American Heart Association Hypertension Scientific Sessions 2026. In the Launch-HTN trial, 46% of participants with difficult-to-treat hypertension achieved the AHA/ACC systolic blood pressure target of <130 mmHg with lorundrostat 50 mg. In the Explore-OSA trial, lorundrostat reduced morning systolic blood pressure by 11.1 mmHg at Week 4. Both trials showed favorable safety and tolerability profiles for lorundrostat.
How this was made
The 30-second read
Why it matters
The new data provide the first public efficacy readout from the pivotal Launch‑HTN trial, a key milestone for the company's commercial prospects.
Market read
First disclosure of pivotal trial results; likely to move MLYS stock and influence sector sentiment.
What to watch
Potential safety concerns or competitive trials in the same space could temper enthusiasm.
Background
Mineralys Therapeutics (Nasdaq: MLYS) focuses on aldosterone‑targeted therapies for resistant hypertension and related comorbidities.
Ticker impact
Mineralys Therapeutics presented new Phase 3 Launch-HTN trial data showing 46% of participants reached SBP <130 mmHg and 70% achieved ≥10 mmHg reduction.
likely upward pressure as market prices in the efficacy data
First disclosure of Phase 3 outcomes for a hypertension drug; data are material for valuation and pipeline expectations.
Market effects
Hypertension therapeutics sector may see increased interest and valuation uplift for peers developing aldosterone synthase inhibitors.
US biotech market could see modest gains as investors reprice pipeline prospects.
Limited to biotech investors; no broad macro impact.
Counterpoint
If the data fail to translate into regulatory approval or commercial uptake, the rally could be short-lived.
Key entities
- companyMineralys Therapeutics
Biopharma developing lorundrostat for hypertension and related conditions.
- drugLorundrostat
Investigational aldosterone synthase inhibitor.
